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Abstract: Intake of industrially produced trans fatty acids (iTFAs) has previously been associated with
dyslipidemia, insulin resistance, hypertension and inflammation, as well as increased cardiovascular
(CV) morbidity and mortality. iTFA intake declined in Norway after the introduction of legislative
bans against iTFA consumption. However, the relationship between the current iTFA intake and CV
health is unclear. The aim of the present study was to investigate the association between current
iTFA intake, reflected by plasma iTFA levels, and established CV risk factors. We also examined the
associations between plasma ruminant TFA levels and CV risk factors. In this cross-sectional study,
we included 3706 participants from a Norwegian general population, born in 1950 and residing in
Akershus County, Norway. The statistical method was multivariable linear regression. Plasma iTFA
levels were inversely associated with serum triglycerides (p < 0.001), fasting plasma glucose (p < 0.001),
body mass index (p < 0.001), systolic and diastolic blood pressure (p = 0.001 and p = 0.03) and C-reactive
protein (p = 0.001). Furthermore, high plasma iTFA levels were associated with higher education
and less smoking and alcohol consumption. We found that plasma ruminant trans fatty acids (rTFA)
levels were favorably associated with CV risk factors. Furthermore, plasma iTFA levels were inversely
associated with CV risk factors. However, our results might have been driven by lifestyle factors.
Overall, our findings suggest that the current low intake of iTFAs in Norway does not constitute a
threat to CV health.
Keywords: industrial trans fatty acids; ruminant trans fatty acids; cardiovascular health; legislative
bans; cardiovascular risk factors
1. Introduction
Trans fatty acids (TFAs) are unsaturated fatty acids with at least one double bond in trans
configuration [1]. The two major sources of TFAs are partially hydrogenated vegetable oils,
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found in various industrially prepared foods, and in dairy and meat products from ruminants [1].
Epidemiological studies have shown a strong association between intake of TFAs, predominantly
industrial produced TFAs (iTFAs), and risk of cardiovascular (CV) disease [2]. The first major study
was published in the early ‘90 s [3], followed by numerous studies consistently reporting harmful
influence of iTFAs on CV health [4–7]. Therefore, the intake of iTFAs was considered a major public
health problem, forcing governments around the world to take legislative action to reduce iTFA content
in foods [8,9]. In addition, cooperative efforts by food industries, voluntarily excluding iTFA-rich
products from their assortment and providing better food labelling for consumers, resulted in a further
reduction of iTFA consumption [1]. In 2003, the World Health Organization recommended to limit the
intake of iTFAs to <1% of overall energy consumption [10].
In Norway, the total TFA intake was approximately 5% of overall energy consumption during
the late ‘50 s, gradually decreasing over the next decades, mainly due to reduction in the use of
margarines [11]. A large Norwegian cohort study, including participants between 1974 and 1988,
reported a positive association between consumption of iTFAs and CV death [12]. The mean intake of
iTFAs was 0.9–1.6% of energy consumption during the study period. Since then, the impact of iTFAs
on CV health has not been evaluated in a Norwegian general population.
There is an increased risk of CV disease even at low levels of iTFAs, and an intake of <0.5% of
overall energy consumption might be necessary to avoid adverse effects [2]. Whether the current iTFA
consumption correlates with established CV risk factors is not known. Moreover, as a consequence
of reduced iTFA consumption, ruminant TFAs (rTFAs) are now the major TFAs in the daily Nordic
diet [13], but the relationship between rTFAs and CV health has been less studied. Accordingly, in this
study, the aim was to examine the associations between the current intake of iTFAs, reflected by plasma
phospholipid levels [14], and CV risk factors in a middle-aged Norwegian community-acquired cohort.
In addition, we examined the association between current rTFA intake and CV risk factors.
2. Materials and Methods
2.1. Study Cohort
The Akershus Cardiac Examination (ACE) 1950 Study is a collaborative project between Akershus
University Hospital and Bærum Hospital, Vestre Viken Hospital Trust, Norway. It is a population-based
cohort study aimed to examine CV health of individuals born in 1950 and residing in Akershus County,
Norway. The study design has previously been presented in detail [15]. From a total of 5827 eligible
individuals invited for participation, 3706 (64%) were enrolled in the study (Figure 1). The remaining
2121 (36%) declined participation or did not respond.
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2.2. Study Variables
Participants were interviewed regarding medical history, diet, education, physical activity and
smoking habits. Cerebrovascular and coronary artery disease were self-reported. Cerebrovascular
disease was classified as history of stroke or cerebral hemorrhage, while coronary artery disease
was defined as history of acute myocardial infarction or having undergone percutaneous coronary
intervention or coronary artery bypass graft operation. Dietary data were self-reported and collected
using a previously validated questionnaire [16], where the participant indicated type of dietary item
and frequency of intake. Higher education was defined as >12 years of formal education, such as
college or university education at any level. High physical activity was self-reported and defined
as vigorous-intensity exercise for more than 30 min, at least twice weekly [17]. Smoking habits
were recorded as either current smoker or previous/non-smoker. Alcohol consumption was recorded
as intake of alcohol two times or more per week. We defined hypertension as current use of any
anti-hypertensive medication, or as mean systolic blood pressure ≥140 mmHg or mean diastolic
blood pressure ≥90 mmHg obtained from three measurements in sitting position after 10 min rest [18].
The World Health Organization criterion (body mass index [BMI, kg/m2] ≥30) was used to define
obesity [19].
Blood samples were drawn after fasting overnight, immediately frozen and stored at −80 ◦C.
We defined hypercholesterolemia as current use of any lipid-lowering agent or total serum cholesterol
≥6.2 mmol/L or low-density lipoprotein (LDL) cholesterol ≥4.1 mmol/L [20]. Diabetes mellitus (DM)
was defined as current use of any glucose-lowering medication, self-reported DM or both fasting
plasma glucose (FPG) ≥7.0 mmol/L and glycated hemoglobin (HbA1c) ≥6.5% [21]. The Chronic
Kidney Disease Epidemiology Collaboration equation [22] was used to calculate estimated glomerular
filtration rate (eGFR), and chronic kidney disease stages 3–5 were defined as eGFR <60 mL/min/1.73 m2.
C-reactive protein (CRP) was measured using standard assay. Carotid intima-media thickness (cIMT)
of the left and right common carotid arteries were assessed by ultrasound examination, and mean
cIMT was obtained as previously described [23].
Samples of frozen plasma were sent to The Lipid Research Center, Aalborg University Hospital
for phospholipid fatty acid determination by gas chromatography. We used modified Folch and
Burge methods to extract total lipids from serum and to isolate the phospholipid fraction from
other lipids [24]. A Varian 3900 gas chromatograph (Varian, Middleburg, The Netherlands) with
60 m × 0.25 mm capillary columns was used for fatty acids analysis. Individual fatty acids were
identified and quantified as weight percentage (wt%) of total plasma phospholipid fatty acids. Fatty
acid analysis was not performed in 23 participants because of inadequate plasma volume (Figure 1).
We defined vaccenic acid and trans-conjugated-linoleic acid as rTFAs [25]. All other TFAs, such as
trans-elaidic acid, 18:1d6-8t and 18:3ttt were defined as iTFAs.
2.3. Statistical Analysis
Quartiles of plasma iTFA levels were used for the presentation of clinical and demographic data.
Results are given as mean values (standard deviations) for normally distributed data, median values
(inter-quartile ranges) for skewed data (serum triglycerides, FPG, HbA1c and CRP) and percentages
for categorical data. Differences between quartiles of plasma iTFA levels were examined by using
ANOVA for normally distributed continuous variables, the Kruskal-Wallis test for skewed variables
and Chi square test for binary data.
We evaluated associations between plasma iTFA and rTFA levels and CV risk factors with
multivariable linear regression, after testing assumptions for linearity. Separate models were created for
each CV risk factor to examine associations between industrial and ruminant TFAs and various CV risk
factors individually. Adjustments were made with predefined candidate variables. The simultaneous
entry method was used for all models. To obtain normal distribution, skewed variables such as
triglycerides, FPG, HbA1c and CRP were logarithmically transformed. Thus, for these variables, the
presented unstandardized regression coefficients (Unstd. β-coeff.) and corresponding 95% confidence
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intervals (CI) represent the anti-logarithm of acquired results. Unstd. β-coeff. with corresponding
95% CI, standardized regression coefficients (Std. β-coeff.), p-values and explained variance (R2) for
the univariable models and fully adjusted final models are presented in the tables. Statistics were
preformed using SPSS® version 25.0 (IBM, New York, NY, US) and STATA 16 (StataCorp LP, Texas,
TX, USA).
2.4. Ethics
This study was performed according to the Declaration of Helsinki guidelines. Regional Ethics
Committee for Medical and Health Research Ethics approved all procedures involving research study
participants (September 7th, 2011. Reference number 2011/1475). Participants gave written informed
consents before final enrolment.
3. Results
3.1. Demographics
Demographics and clinical characteristics of participants stratified according to quartiles of plasma
iTFA levels are given in Table 1. Plasma iTFA levels ranged from 0.09 to 0.62 wt%, with a median level
of 0.20 wt% (interquartile range 0.13 to 0.27 wt%) (Figure 2).
Table 1. Characteristics of participants according to quartiles of industrial trans fatty acid levels.
All Participants Quartile 1 Quartile 2 Quartile 3 Quartile 4 p for Trend p for Q1 vs. Q4
Industrial trans
fatty acid level, wt% 0.09–0.62 ≤0.17 0.18–0.20 0.21–0.24 ≥0.25
Number of
participants 3683 1025 886 893 879
Age, years 63.9 (0.6) 63.8 (0.6) 63.9 (0.7) 63.9 (0.7) 64.0 (0.7) <0.001 <0.001
Sex (Male), % 51.3 (n = 1890) 59.1 (n = 606) 54.1 (n = 479) 48.7 (n = 435) 42.1 (n = 370) <0.001 <0.001
Weekly intake of
milk, 1 glass or
more, %
56.5 (n = 2042) 55.4 (n = 560) 55.2 (n = 476) 58.0 (n = 508) 57.6 (n = 498) 0.52 0.34
Use butter or
margarine in
cooking, %
50.4 (n = 1782) 50.1 (n = 496) 51.8 (n = 441) 50.6 (n = 431) 48.9 (n = 414) 0.68 0.61
Use oil in cooking,
% 48.2 (n = 1706) 48.6 (n = 481) 46.1 (n = 392) 48.3 (n = 411) 49.8 (n = 422) 0.47 0.60
Weekly intake of
fast food, once or
more, %
18.1 (n = 651) 20.7 (n = 208) 18.2 (n = 157) 18.9 (n = 165) 14.0 (n = 121) 0.002 <0.001
Current smoker, % 14.5 (n = 530) 16.7 (n = 171) 14.9 (n = 131) 13.1 (n = 115) 13.0 (n = 113) 0.06 0.02
Alcohol
consumption, (≥2
times weekly), %
47.4 (n = 1739) 55.4 (n = 568) 50.0 (n = 440) 43.6 (n = 388) 39.2 (n = 343) <0.001 <0.001
Alcohol
consumption, >5
units at same
occasion, %
46.6 (n = 1701) 56.4 (n = 576) 49.1 (431) 43.5 (n = 383) 35.9 (n = 311) <0.001 <0.001
Physical activity (≥2
times weekly), % 61.7 (n = 2240) 59.1 (n = 600) 61.5 (n = 536) 63.4 (n = 554) 63.4 (n = 550) 0.17 0.06
Higher education,
% 46.5 (n = 1708) 39.0 (n = 399) 48.6 (n = 429) 48.8 (n = 435) 50.7 (n = 445) <0.001 <0.001
Hypertension, % 62.0 (n = 2282) 70.5 (n = 723) 60.2 (n = 549) 59.6 (n = 532) 54.4 (n = 478) <0.001 <0.001
Hypercholesterolemia,
% 52.6 (n = 1931) 57.3 (n = 584) 50.5 (n = 446) 54.4 (n = 485) 47.4 (n = 416) <0.001 <0.001
Cerebrovascular
disease, % 3.7 (n = 138) 3.2 (n = 33) 3.3 (n = 29) 4.7 (n = 42) 3.9 (n = 34) 0.30 0.44
Coronary artery
disease, % 7.0 (n = 259) 9.7 (n = 99) 6.9 (n = 61) 6.2 (n = 55) 5.0 (n = 44) 0.001 <0.001
Diabetes mellitus, % 8.5 (n = 313) 12.9 (n = 132) 7.8 (n = 69) 6.7 (n = 60) 5.9 (n = 52) <0.001 <0.001
Obesity (BMI ≥ 30),
% 22.6 (n = 831) 27.7 (n = 284) 21.3 (n = 189) 23.2 (n = 207) 17.2 (n = 151) <0.001 <0.001
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Table 1. Cont.
All Participants Quartile 1 Quartile 2 Quartile 3 Quartile 4 p for Trend p for Q1 vs. Q4
CKD stages 3–5
(eGFR <60 mL/min
× 1.73 m2), %
3.9 (n = 142) 3.9 (n = 40) 2.6 (n = 23) 3.7 (n = 33) 5.3 (n = 46) 0.04 0.16
Medication, %
Diuretics 3.1 5.0 2.3 2.5 2.3 0.001 <0.001
Beta blockers 13.4 18.6 13.7 10.8 9.6 <0.001 <0.001
Calcium-channel
blockers 8.1 10.7 9.0 6.7 5.7 <0.001 <0.001
ACEi or ARB 26.9 34.2 26.5 24.3 21.5 <0.001 <0.001
Lipid-lowering
drugs 26.1 31.4 27.3 24.3 20.7 <0.001 <0.001
Glucose-lowering
drugs 5.4 7.6 5.4 4.6 3.6 <0.001 <0.001
Systolic blood
pressure, mmHg 138 (19) 140 (19) 138 (19) 137 (19) 136 (18) <0.001 <0.001
Diastolic blood
pressure, mmHg 77 (10) 78 (10) 77 (10) 77 (10) 76 (10) <0.001 <0.001
HDL cholesterol,
mmol/L 1.5 (0.5) 1.5 (0.5) 1.5 (0.5) 1.6 (0.5) 1.6 (0.5) <0.001 <0.001
LDL cholesterol,
mmol/L 3.3 (1.0) 3.3 (1.0) 3.2 (1.0) 3.4 (1.0) 3.3 (1.0) 0.01 0.22
Triglycerides,
mmol/L 1.2 (0.4–2–0) 1.4 (0.5–2.3) 1.2 (0.3–2.1) 1.1 (0.4–1.8) 1.0 (0.3–1.7) <0.001 <0.001
FPG, mmol/L 5.3 (4.5–6.1) 5.4 (4.5–6.3) 5.3 (4.5–6.1) 5.2 (4.4–6.0) 5.2 (4.4–6.0) <0.001 <0.001
HbA1c, % 5.7 (5.3–6.1) 5.7 (5.2–6.2) 5.7 (5.3–6.1) 5.7 (5.3–6.1) 5.7 (5.3–6.1) 0.004 0.002
Body mass index
(BMI), kg/m2 27.1 (4.4) 28.0 (4.4) 27.2 (4.3) 27.0 (4.5) 26.2 (4.3) <0.001 <0.001
eGFR, ml/min ×
1.73m2 83 (11.9) 83 (12.2) 84 (11.4) 83 (11.7) 83 (12.4) 0.18 0.14
cIMT, mm 0.73 (0.1) 0.73 (0.1) 0.73 (0.1) 0.73 (0.1) 0.72 (0.1) 0.52 0.17
CRP, mg/L 1.5 (1.4–1.6) 1.5 (1.4–1.6) 1.5 (1.4–1.6) 1.5 (1.4–1.6) 1.5 (1.4–1.6) - -
Marine n-3 PUFAs,
wt% 8.1 (2.6) 8.2 (2.8) 8.2 (2.7) 8.0 (2.5) 7.9 (2.5) 0.08 0.03
LA, wt% 20.8 (3.0) 20.1 (3.0) 20.6 (2.9) 21.1 (2.8) 21.4 (2.9) <0.001 <0.001
AA, wt% 9.2 (2.0) 9.5 (2.1) 9.3 (2.1) 9.2 (2.0) 8.9 (2.0) <0.001 <0.001
SFA, wt% 42.4 (0.9) 42.8 (0.8) 42.5 (0.8) 42.3 (0.7) 42.0 (0.9) <0.001 <0.001
MUFA, wt% 10.3 (1.4) 10.3 (1.5) 10.3 (1.4) 10.2 (1.4) 10.3 (1.3) 0.17 0.84
Results are given as mean values (standard deviation) for continuous data, median values (inter-quartile ranges)
for skewed data and percentages for categorical data. Differences between the quartiles were evaluated using
Chi square for binary data, the Kruskal-Wallis test for triglycerides, FPG, HbA1c and CRP, and ANOVA for other
continuous data. Fatty acids are given as weight percentage (wt%) of total plasma phospholipid fatty acids.
Abbreviations: BMI: Body mass index. CKD: Chronic kidney disease. eGFR: Estimated glomerular filtration rate
(CKD-EPI formula). ACEi: Angiotensin converting enzyme inhibitor. ARB: Angiotensin receptor blocker. HDL:
High density lipoprotein. LDL: Low density lipoproteins. FPG: Fasting plasma glucose. HbA1c: Hemoglobin A1c.
cIMT: Carotid intima-media thickness. CRP: C-reactive protein. PUFA: Polyunsaturated fatty acids. LA: Linoleic
acid. AA: Arachidonic acid. SFA: Saturated fatty acids. MUFA: Monounsaturated fatty acids.
There was a higher proportion of females in the upper quartile of plasma iTFA levels. Using the
lower quartile of plasma iTFA levels as reference, participants in the upper quartile were more educated,
had a lower prevalence of smoking and consumed alcohol less often. Furthermore, participants in the
upper quartile of plasma iTFA levels had a lower prevalence of comorbidities, such as hypertension,
hypercholesterolemia, coronary artery disease, DM and obesity, and less use of antihypertensive,
lipid-lowering and glucose-lowering drugs.
Nutrients 2020, 12, 1419 6 of 13
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Figure 2. Distribution of industrial and ruminant trans fatty acids measured in weight percentage
(wt%) of total plasma phospholipid fatty acids.
Demographics and clinical characteristics of participants stratified according to quartiles of plasma
rTFA levels are presented in Supplementary Table S1. Plasma rTFA levels ranged from 0.14 to 2.87 wt%,
with a median level of 1.60 wt% (interquartile range 1.30 to 1.90 wt%) (Figure 2). Using the lower
quartile of plasma rTFA levels as reference, participants in the upper quartile had a higher consumption
of margarine and butter, a higher prevalence of smoking and consumed alcohol more often. In addition,
they had a lower prevalence of DM, but higher prevalence of coronary artery disease and used more
lipid-lowering drugs.
3.2. Plasma iTFA Levels and CV Risk Factors
Unadjusted and multivariable adjusted associations between plasma iTFA levels and CV risk
factors are presented in Table 2. High levels of plasma iTFAs were associated with lower serum
triglycerides, FPG levels, BMI, systolic and diastolic blood pressure and CRP levels. We found no
associations between plasma iTFA levels and serum high-density lipoprotein (HDL) or LDL cholesterol
levels, HbA1c, eGFR or cIMT.
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Table 2. Associations between plasma industrial trans fatty acid levels and cardiovascular risk factors.
Univariable Linear Regression Analysis
Cardiovascular Risk Factors n Unstd. β-coeff. (95% CI) Std. β-coeff. p R2
HDL cholesterol, mmol/L 3680 1.02 (0.72, 1.32) 0.11 <0.001 0.01
LDL cholesterol, mmol/L 3657 0.55 (−0.05, 1.15) 0.03 0.07 0.001
Triglycerides, mmol/L 3680 −7.89 (−10.57, −5.89) −0.22 <0.001 0.05
FPG, mmol/L 3675 −1.62 (−1.81, −1.47) −0.15 <0.001 0.02
HbA1c, % 3669 −1.13 (−1.21, −1.06) −0.07 <0.001 0.004
BMI, kg/m2 3683 −13.50 (−16.23, −10.78) −0.16 <0.001 0.03
SBP 3679 −30.09 (−41.77, −18.42) −0.08 <0.001 0.01
DBP 3679 −16.45 (−22.70, −10.20) −0.09 <0.001 0.01
eGFR, mL/min × 1.73m2 3664 −5.43 (−12.90, 2.04) −0.02 0.15 0.00
cIMT, mm 3661 −0.07 (−0.14, 0.004) −0.03 0.07 0.001
CRP, mg/L 3669 −3.26 (−4.90, −2.14) −0.09 <0.001 0.01
Multivariable Linear Regression Analysis
Cardiovascular Risk Factors n Unstd. β-coeff. (95% CI) Std. β-coeff. p R2
HDL cholesterol, mmol/L a 3640 0.20 (−0.06, 0.46) 0.02 0.14 0.30
LDL cholesterol, mmol/L b 3617 −0.44 (−0.97, 0.10) −0.02 0.11 0.27
Triglycerides, mmol/L c 3640 −4.19 (−5.52, −3.17) −0.15 <0.001 0.21
FPG, mmol/L d 3636 −1.19 (−1.29, −1.09) −0.05 <0.001 0.39
HbA1c, % e 3630 −1.01 (−1.06, 1.04) −0.004 0.77 0.38
BMI, kg/m2 f 3612 −11.22 (−13.90, −8.53) −0.13 <0.001 0.12
SBP g 3640 −20.62 (−32.53, −8.72) −0.06 0.001 0.03
DBP h 3640 −6.68 (−12.80, −0.57) −0.03 0.03 0.12
eGFR, mL/min × 1.73m2 i 3624 −3.08 (−10.80, 4.61) −0.01 0.43 0.03
cIMT, mm j 3625 0.04 (−0.03, 0.11) 0.02 0.27 0.05
CRP, mg/L k 3629 −2.07 (−3.14, −1.37) −0.06 0.001 0.07
a Sex, smoking, alcohol consumption, DM, BMI, lipid lowering drugs. b Sex, smoking, alcohol consumption, DM,
BMI, lipid lowering drugs. c Sex, smoking, alcohol consumption, DM, BMI, lipid lowering drugs. d Sex, smoking,
alcohol consumption, BMI, glucose-lowering drugs. e Sex, smoking, alcohol consumption, BMI, glucose-lowering
drugs. f Sex, smoking, alcohol consumption, DM, physical activity, higher education. g Sex, smoking, alcohol
consumption, DM, BMI. h Sex, smoking, alcohol consumption, DM, BMI. i Sex, smoking, alcohol consumption,
DM, BMI, hypertension. j Sex, smoking, alcohol consumption, DM, BMI, lipid lowering drugs, hypertension. k Sex,
smoking, alcohol consumption, DM, BMI. Unstandardized β coefficients (Unstd. β-coeff.) with corresponding
95% confidence intervals (CI), standardized β coefficients (Std. β-coeff.), p-values and explained variance (R2)
are given for plasma industrial trans fatty acid levels in univariable analysis and the fully adjusted multivariable
models. Abbreviations: BMI: Body mass index. cIMT: Carotid intima-media thickness. CRP: C-reactive protein.
DBP: Diastolic blood pressure. DM: Diabetes mellitus. eGFR: Estimated glomerular filtration rate. FPG: Fasting
plasma glucose. HbA1c: Hemoglobin A1c. HDL: High-density lipoprotein. LDL: Low-density lipoprotein. SBP:
Systolic blood pressure.
3.3. Plasma rTFA Levels and CV Risk Factors
Unadjusted and multivariable adjusted associations between plasma rTFA levels and CV risk
factors are presented in Table 3. High levels of plasma rTFAs were associated with higher serum HDL
and lower serum LDL cholesterol levels, serum triglycerides, FPG levels, HbA1c, BMI, systolic and
diastolic blood pressure. We found no associations between plasma rTFA levels and eGFR, cIMT or
CRP levels.
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Table 3. Associations between plasma ruminant trans fatty acid levels and cardiovascular risk factors.
Univariable Linear Regression Analysis
Cardiovascular Risk Factors n Unstd. β-coeff. (95% CI) Std. β-coeff. p R2
HDL cholesterol, mmol/L a 3680 0.25 (0.18, 0.32) 0.12 <0.001 0.01
LDL cholesterol, mmol/L b 3657 −0.62 (−0.76, −0.49) −0.15 <0.001 0.02
Triglycerides, mmol/L c 3680 −1.51 (−1.61, −1.41) −0.20 <0.001 0.04
FPG, mmol/L d 3675 −1.11 (−1.14, −1.08) −0.14 <0.001 0.02
HbA1c, % e 3669 −1.08 (−1.10, −1.07) −0.19 <0.001 0.04
BMI, kg/m2 f 3683 −2.60 (−3.21, −1.99) −0.14 <0.001 0.02
SBP g 3679 −5.14 (−7.75, −2.53) −0.06 <0.001 0.004
DBP h 3679 −3.40 (−4.80, −2.01) −0.08 <0.001 0.01
eGFR, mL/min × 1.73m2 i 3664 −0.01 (−1.68, 1.66) 0.00 0.99 0.00
cIMT, mm j 3661 −0.002 (−0.02, 0.01) −0.004 0.83 0.00
CRP, mg/L k 3669 −1.12 (−1.23, −1.02) −0.04 0.01 0.001
Multivariable Linear Regression Analysis
Cardiovascular Risk Factors n Unstd. β-coeff. (95% CI) Std. β-coeff. p R2
HDL cholesterol, mmol/L a 3640 0.16 (0.10, 0.22) 0.08 <0.001 0.27
LDL cholesterol, mmol/L b 3617 −0.42 (−0.54, −0.30) −0.10 <0.001 0.28
Triglycerides, mmol/L c 3640 −1.37 (−1.46, −1.29) −0.15 <0.001 0.21
FPG, mmol/L d 3636 −1.06 (−1.08, −1.04) −0.08 <0.001 0.39
HbA1c, % e 3630 −1.06 (−1.07, −1.04) −0.13 <0.001 0.39
BMI, kg/m2 f 3612 −1.96 (−2.55, −1.37) −0.10 <0.001 0.10
SBP g 3640 −3.31 (−5.92, −0.69) −0.04 0.01 0.03
DBP g 3640 −2.98 (−4.32, −1.64) −0.07 <0.001 0.12
eGFR, mL/min × 1.73m2 i 3624 −0.83 (−2.52, 0.85) −0.02 0.33 0.03
cIMT, mm j 3625 0.01 (−0.01, 0.02) 0.01 0.56 0.05
CRP, mg/L k 3629 −1.03 (−1.12, 1.04) −0.01 0.49 0.07
a Sex, smoking, alcohol consumption, DM, BMI, lipid lowering drugs. b Sex, smoking, alcohol consumption, DM,
BMI, lipid lowering drugs. c Sex, smoking, alcohol consumption, DM, BMI, lipid lowering drugs. d Sex, smoking,
alcohol consumption, BMI, glucose-lowering drugs. e Sex, smoking, alcohol consumption, BMI, glucose-lowering
drugs. f Sex, smoking, alcohol consumption, DM, physical activity, higher education. g Sex, smoking, alcohol
consumption, DM, BMI. h Sex, smoking, alcohol consumption, DM, BMI. i Sex, smoking, alcohol consumption,
DM, BMI, hypertension. j Sex, smoking, alcohol consumption, DM, BMI, lipid lowering drugs, hypertension. k Sex,
smoking, alcohol consumption, DM, BMI. Unstandardized β coefficients (Unstd. β-coeff.) with corresponding
95% confidence intervals (CI), standardized β coefficients (Std. β-coeff.), p-values and explained variance (R2)
are given for plasma ruminant trans fatty acid levels in univariable analysis and the fully adjusted multivariable
models. Abbreviations: BMI: Body mass index. cIMT: Carotid intima-media thickness. CRP: C-reactive protein.
DBP: Diastolic blood pressure. DM: Diabetes mellitus. eGFR: Estimated glomerular filtration rate. FPG: Fasting
plasma glucose. HbA1c: Hemoglobin A1c. HDL: High-density lipoprotein. LDL: Low-density lipoprotein. SBP:
Systolic blood pressure.
4. Discussion
The main finding in the present study was that plasma rTFA levels were favorably associated
with CV risk factors. Furthermore, plasma iTFA levels were inversely associated with several risk
factors for CV disease, such as serum triglycerides, FPG, BMI, systolic and diastolic blood pressure and
CRP levels. These results are in apparent contrast to the established harmful effects of iTFA on CV
health, and might have been confounded by lifestyle related factors. Our findings suggest that the
current low intake of iTFAs in Norway does not constitute a threat to CV health.
4.1. Plasma iTFA Levels and CV Risk Factors
iTFAs are suggested to promote dyslipidemia, inflammation and endothelial dysfunction [26,27].
These adverse effects of iTFAs have been related to the trans double bonds, changing their configuration
and chemical properties compared with their cis-isomers [28].
Nutrients 2020, 12, 1419 9 of 13
iTFAs have been used in the food industry since the 1950 s [29]. They were produced by partial
hydrogenation of vegetable and fish oils, turning them into semi-solid fats that were cheap to produce,
and with desirable physical properties like long shelf life and temperature stability [1]. Consequently,
iTFAs were widely used in products like margarines, bakery products, crackers and deep-fried
food [29]. The negative effects of iTFAs first became apparent from studies performed during the last
few decades [2,3,30]. In a meta-analysis of four prospective studies, a 2% increase in energy intake from
iTFAs was associated with a 23% increase in incident of CV disease [2]. From a nutritional standpoint,
iTFAs were potentially harmful, and had no apparent health benefits. Consequently, several countries
introduced legislation mandating the reduction of iTFA concentrations in foods [31], with Denmark
being the first country to do so in 2003 [8]. Although the Norwegian iTFA-legislation was not passed
before 2014 [31], the iTFA consumption was reduced shortly after the Danish legislation, mostly due to
societal pressure and efforts by Regulatory Authorities and the Norwegian food industry [11]. In 2012,
the dietary intake of total TFAs was <1% of total energy consumption in Norway [32].
We have previously shown a reduction in median plasma iTFA levels from 0.29 wt% in years
1999–2004 to 0.20 wt% in years 2005–2011 in a Norwegian population of kidney transplant recipients [33].
Similarly, the median plasma iTFA level was 0.20 wt% in the present study, suggesting a persistent
low iTFA consumption in the Norwegian population. iTFAs have previously been associated
with hypertriglyceridemia, insulin resistance, adiposity, hypertension and inflammation [26,34–37].
In contrast, we found inverse associations between plasma iTFA levels and serum triglycerides,
FPG, BMI, systolic and diastolic blood pressure and CRP levels. In addition, the highest levels of
plasma iTFAs were found in participants with high education, a healthy lifestyle with less fast food
consumption, and lower prevalence of comorbidities.
These findings were unexpected and seemingly paradoxical. The detrimental effects of iTFAs
are scientifically established, thus, the biological plausibility of high iTFA intake being beneficial to
CV health seems highly unlikely. In Norway, potential sources of iTFAs might be consumption of
imported food products that still contain high levels of iTFAs [38], or traveling to destinations with
less restrictive or no iTFA-bans. However, we do not have data to support these assumptions, and the
reasons for these findings remain to be elucidated. It is worth noticing that our results are characterized
by small regression coefficients, signaling no associations between plasma iTFA levels and CV risk
factors, rather than an inverse relationship. Our findings suggest that the low levels of plasma iTFAs
observed in this cohort are perhaps no longer of clinical relevance, and that the inverse associations
between plasma iTFA levels and CV risk factors might have been confounded by factors related to
healthy lifestyle, not fully adjusted for in the regression analyses.
4.2. Plasma rTFA Levels and CV Risk Factors
Reduction in iTFA consumption has not affected the rTFA intake, at least not in Scandinavian
countries, where the intake has been relative constant since the 1990 s [39,40]. Epidemiological studies
have reported a nonsignificant trend towards an inverse association between rTFA intake and risk of
CV disease [3,5]. Reasons for these findings are unclear, but might be related to different biological
properties of rTFAs compared to iTFAs, or the presence of other substances in dairy and meat products
that might be protective against CV disease [1].
A moderate intake of rTFAs has resulted in a favorable lipid profile, with higher serum HDL and
lower serum LDL cholesterol levels, in clinical trials [41]. However, a high intake of rTFAs increase
serum LDL cholesterol levels [41]. In this study, plasma rTFA levels were positively associated with
serum HDL cholesterol levels and inversely associated with serum LDL cholesterol levels and serum
triglycerides. These findings indicate favorable relationships between high rTFA intake and blood
lipids. However, participants in the upper quartile of plasma rTFA levels used more lipid-lowering
drugs, which might have confounded the association between plasma rTFA levels and serum LDL
cholesterol levels.
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We also found inverse associations between plasma rTFA levels and FPG levels and HbA1c.
In addition, participants with the highest plasma rTFA levels had a lower prevalence of DM, a finding
in line with previous epidemiological studies reporting an inverse association between rTFA intake and
incident DM [42,43]. Suggested mechanisms for this observation are rTFA-mediated increased insulin
sensitivity and skeletal muscle glucose-uptake [42]. However, in clinical trials, diet rich in vaccenic
acid, the major rTFA, has not shown any effect on fasting insulin or glucose [44]. Thus, the relationship
between rTFA intake and glucose metabolism remains unclear. Finally, we found inverse associations
between plasma rTFA levels and BMI and blood pressure. Epidemiological data on rTFA intake and
BMI are inconclusive [45,46], and no effect of rTFAs consumption on blood pressure has been seen in
clinical trials [47]. Interestingly, participants in the upper quartile of plasma rTFA levels had an overall
unhealthier lifestyle with higher consumption of margarine and butter, higher prevalence of smoking
and alcohol consumption. This might have contributed to the higher prevalence of coronary artery
disease among these participants.
We found overall favorable associations between plasma rTFA levels and CV risk factors. However,
similar to plasma iTFAs levels, the demonstrated associations to CV risk factors were weak, although
statistically significant.
4.3. iTFA Legislation and Global Aspects
In this paper we briefly summarize the iTFA story in Norway, with a snapshot of the current
status, characterized by a low iTFA intake that is unlikely to increase in the future. As pointed out
by Brouwer et al. in the article “Trans fatty acids and cardiovascular health: research completed?”,
due to well documented detrimental effects the use of iTFAs is nearly eliminated in many countries
and unlikely to be brought back into the food industry [48]. Unfortunately, there are still large regions
worldwide, such as North America and the Middle East, where the consumption of iTFAs by far
exceeds the recommendations given by the World Health Organization [49,50], reasons for this being
ineffective strategies for voluntary iTFA reduction in foods and the lack of legislative iTFA bans [31].
In a recent publication, Wilczek et al. expresses the urgent need for such legislative action due to
alarmingly high iTFA consumption in Eastern and South-Eastern Europe [29]. It is estimated that the
Danish policy against iTFA reduced CV disease mortality by 14.2 deaths per 100,000-person years on
average in the period 2004–2006 [51]. We hope that such findings, as well as our own, can inspire
governments in countries with a high iTFA intake to implement measures that can effectively reduce
the iTFA consumption.
4.4. Strengths and Limitations
The present study has several strengths, including a well-described large study population with
little missing data. All the study participants were born in 1950, removing age as possible confounding
element. In addition, plasma phospholipid TFA levels were determined by gas chromatography, giving
an estimate of TFA intake [14]. One of the main limitations is the cross-sectional study design. We do
not have dietary data to determine the absolute iTFA or rTFA intake. Reverse causality bias cannot be
ruled out. Furthermore, the influence of residual confounding on the associations between plasma
iTFA and rTFA levels and CV risk factors cannot be excluded, despite adjustments for covariates.
Finally, our result might have limited generalizability to other age groups and ethnicities.
5. Conclusions
In this cross-sectional study of Norwegian individuals born in 1950, plasma rTFA and iTFA levels
were favorably associated with CV risk factors. Plasma iTFA levels were low, and the weak associations
to CV risk factors might have been confounded by factors related to a healthy lifestyle, such as less
smoking and alcohol consumption and a higher educational level. Overall, our findings suggest that
the current low intake of iTFAs in Norway no longer poses a threat to CV health.
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